• (-)-Arctigenin as a MEK1 Inhibitor: Advanced Workflows & Ins

  2026-06-10

  Leverage (-)-Arctigenin’s unique dual action as a MEK1 inhibitor and iNOS expression blocker for precise breast cancer and inflammation research. This guide translates the latest pathway-driven findings into actionable protocols and troubleshooting strategies, empowering researchers to accelerate discovery in tumor microenvironment modeling.

• Torin2 in Apoptosis Assays: Unraveling mTOR and RNA Pol II I

  2026-06-09

  Explore how Torin2, a potent mTOR inhibitor, enables advanced dissection of apoptosis mechanisms beyond transcriptional repression. This article uniquely integrates structural binding insights and RNA Pol II-driven cell death for next-level cancer research assays.

• hiPSC-Derived Intestinal Organoids: A New Standard for Pharm

  2026-06-09

  This study establishes an efficient protocol for generating human pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) as advanced in vitro models for pharmacokinetic research. The findings reveal that hiPSC-IOs recapitulate key metabolic and transporter functions of the human intestinal epithelium, addressing limitations of traditional models and enabling more predictive drug absorption studies.

• RITA (NSC 652287): A New Frontier for Translational Cancer R

  2026-06-08

  This article offers a strategic, mechanistic exploration of RITA (NSC 652287) for translational oncology. It bridges advanced p53-targeted approaches, in vitro assay design, and the evolving landscape of renal carcinoma research, referencing both recent methodological breakthroughs and robust in vivo evidence. Key protocol parameters and critical insights for researchers seeking next-generation apoptosis assays and tumor xenograft models are featured.

• Cefepime (BMY-28142): Precision in CNS Infection and Resista

  2026-06-08

  Explore the advanced use of Cefepime (BMY-28142) in central nervous system infection research, with a focus on resistance dynamics and neurotoxicity considerations. This article delivers unique insights for scientific workflows, referencing the latest epidemiological findings.

• Pexidartinib (PLX3397): Transforming Macrophage Modulation i

  2026-06-07

  This thought-leadership article explores the mechanistic depth and translational potential of Pexidartinib (PLX3397) as a selective CSF1R inhibitor for targeting tumor-associated macrophages (TAMs). By integrating recent breakthroughs in SPP1-directed TAM reprogramming, the piece provides strategic guidance for translational researchers, addresses experimental design challenges, and delineates how Pexidartinib positions itself at the vanguard of macrophage-centric immuno-oncology.

• Triacetin’s Role in Bauhinia divaricata’s Antiadipogenic Act

  2026-06-06

  This article reviews the pharmacological and chemical characterization of Bauhinia divaricata L. extracts in an in vitro antiadipogenic model, highlighting the identification of triacetin as a major bioactive compound. The findings provide mechanistic insight into plant-derived anti-obesity agents and inform further research on synthetic analogs for metabolic regulation.

• Pazopanib Hydrochloride: Multi-Target Kinase Inhibitor in On

  2026-06-05

  Pazopanib Hydrochloride (GW786034) is a potent anti-angiogenic agent approved for renal cell carcinoma and soft tissue sarcoma therapy. Its multi-target tyrosine kinase inhibition profile enables broad anti-tumor activity in preclinical and clinical settings. This article details its mechanism, evidence, and workflow integration for cancer research.

• Pazopanib (GW-786034): Optimizing Angiogenesis Inhibition Wo

  2026-06-05

  Pazopanib (GW-786034) delivers robust VEGFR/PDGFR/FGFR inhibition, enabling advanced cancer research and targeted angiogenesis assays. Discover how to apply this multi-targeted RTK inhibitor in validated workflows, troubleshoot common pitfalls, and leverage the latest insights from ATRX-deficient tumor models.

• InstaBlue Protein Stain Solution: Fast, Sensitive Gel Staini

  2026-06-04

  InstaBlue Protein Stain Solution delivers rapid and sensitive visualization of protein bands in polyacrylamide gels, streamlining workflows by eliminating fixation, washing, and destaining steps. It is ideal for researchers requiring high signal-to-noise detection compatible with mass spectrometry, but is not suitable for applications demanding crosslinking or irreversible fixation.

• HMGB1-Loaded Exosomes Mediate Glomerular Injury in Lupus Nep

  2026-06-04

  This study reveals that podocyte-derived exosomes carrying HMGB1 promote glomerular endothelial cell injury in lupus nephritis by upregulating TRIM27 expression. The findings clarify the mechanistic link between exosomal communication and endothelial dysfunction, highlighting potential intervention points in autoimmune kidney disease.

• Exosomal HMGB1 Drives Glomerular Endothelial Injury in Lupus

  2026-06-03

  This study reveals that podocyte-derived exosomes carrying HMGB1 mediate glomerular endothelial cell (GEC) injury in lupus nephritis by upregulating TRIM27 expression. The findings clarify a mechanistic pathway for endothelial dysfunction in LN and suggest that targeting exosome release or HMGB1 cargo could offer new therapeutic angles.

• Sodium Nitroprusside as a Nitric Oxide Donor in Vascular Res

  2026-06-03

  Sodium Nitroprusside enables precise dissection of vasodilation and platelet function, supporting advanced workflows in sex-difference hypertension research. This guide translates recent mechanistic insights into actionable protocols and troubleshooting tips, empowering researchers to maximize reproducibility and data quality.

• Synthetic Efferocytic Microglia Enable Anti-Inflammatory Aβ

  2026-06-02

  Shao et al. report a novel synthetic efferocytic receptor (SER) that reprograms microglia to selectively clear amyloid-β (Aβ) in Alzheimer’s disease (AD) mouse models without triggering proinflammatory responses. Their work demonstrates that in situ mRNA-mediated microglial engineering enhances Aβ phagocytosis, reduces neuroinflammation, and improves behavioral outcomes, providing a promising blueprint for immune-silent CNS therapies.

• Pazopanib (GW-786034): Precision Protocols for Cancer Resear

  2026-06-02

  Pazopanib (GW-786034) stands out as a multi-targeted RTK inhibitor enabling high-fidelity angiogenesis and tumor growth suppression, particularly in genetically defined cancer models. This guide translates the latest evidence and expert workflows into actionable protocols, troubleshooting steps, and advanced use-cases for researchers leveraging APExBIO’s trusted reagent.

14593 records 5/973 page Previous Next 12345 下5页 Last page